ライブラリ登録: Guest
Critical Reviews™ in Eukaryotic Gene Expression

年間 6 号発行

ISSN 印刷: 1045-4403

ISSN オンライン: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Retinoid Targets for the Treatment of Cancer

巻 16, 発行 3, 2006, pp. 193-210
DOI: 10.1615/CritRevEukarGeneExpr.v16.i3.10
Get accessGet access

要約

Retinoic acid (RA), the most potent natural retinoid, is essential for normal cell growth and differentiation. The RA signaling pathway is multistep, involving the precise regulation of retinoid levels and the control of RA-dependent gene expression in target cells. Within this complex scheme, there are many different aberrations in the RA signaling pathway of tumor cells that have been found to be associated with abnormal cell growth and tumorigenesis. This article reviews the normal pathways of RA signaling, followed by a discussion of the various sites that have been implicated in tumorigenesis and targeted for drug development. Currently, there are several retinoids and one rexinoid approved for the treatment of specific cancers. Future experimentation in drug discovery will continue to explore the efficacy of retinoids/rexinoids, either alone or in combination with other chemotherapeutic agents and/or chromatin remodeling agents, and the development of agents to modulate RA metabolism within cells. It is likely that different drug treatments will be developed that are specifically tailored to the unique point(s) in the RA signaling pathways that are aberrant in specific types of tumor cells.

によって引用された
  1. Withayachumnankul Withawat, Png Gretel M., Yin Xiaoxia, Atakaramians Shaghik, Jones Inke, Lin Hungyen, Ung Benjamin Seam Yu, Balakrishnan Jegathisvaran, Ng Brian W.-H., Ferguson Bradley, Mickan Samuel P., Fischer Bernd M., Abbott Derek, T-Ray Sensing and Imaging, Proceedings of the IEEE, 95, 8, 2007. Crossref

  2. Mongan Nigel P., Gudas Lorraine J., Diverse actions of retinoid receptors in cancer prevention and treatment, Differentiation, 75, 9, 2007. Crossref

  3. Seddon Beatrice M, Whelan Jeremy S, Emerging Chemotherapeutic Strategies and the Role of Treatment Stratification in Ewing Sarcoma, Pediatric Drugs, 10, 2, 2008. Crossref

  4. Trichard Laury, Fattal Elias, Besnard Madeleine, Bochot Amélie, α-Cyclodextrin/oil beads as a new carrier for improving the oral bioavailability of lipophilic drugs, Journal of Controlled Release, 122, 1, 2007. Crossref

  5. Claudel Thierry, Cretenet Gaspard, Saumet Anne, Gachon Frédéric, Crosstalk between xenobiotics metabolism and circadian clock, FEBS Letters, 581, 19, 2007. Crossref

  6. Locker Joseph, Hepatic Complexities of Retinoid Therapy, Journal of Experimental & Clinical Medicine, 2, 2, 2010. Crossref

  7. Wille John J., Park Jong Y., Shealy Y. Fulmer, Cancer Chemopreventive Retinoids: Validation and Analysis of <i>in Vivo</i> and <i>in Vitro</i> Bioassay Results, Journal of Cancer Therapy, 07, 13, 2016. Crossref

  8. Heim Kelly C., Gamsby Joshua J., Hever Mary P., Freemantle Sarah J., Loros Jennifer J., Dunlap Jay C., Spinella Michael J., Capogrossi Maurizio C., Retinoic Acid Mediates Long-Paced Oscillations in Retinoid Receptor Activity: Evidence for a Potential Role for RIP140, PLoS ONE, 4, 10, 2009. Crossref

  9. Radaeva Svetlana, Alcohol, Retinoic Acid, and Cancer, in Alcohol and Cancer, 2011. Crossref

  10. Njar Vincent C. O., Retinoids in Clinical Use, in Nuclear Receptors as Drug Targets, 2008. Crossref

  11. Alwhaibi Abdulrahman, Alenazi Miteb, Almadi Bana, Alotaibi Abdulaziz, Alshehri Sultan M, Shakeel Faiyaz, A practical method for oral administration of isotretinoin in pediatric oncology patient: A case study of neuroblastoma, Journal of Oncology Pharmacy Practice, 2022. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain